Cytek Biosciences Inc (CTKB)
Quick ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||
|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 167,299 | 163,629 | 131,500 | 129,476 | 296,601 | 341,523 | 349,894 | 362,506 |
| Short-term investments | US$ in thousands | 95,111 | 124,392 | 167,294 | 169,519 | 44,548 | — | — | — |
| Receivables | US$ in thousands | 55,928 | 55,402 | 49,624 | 43,100 | 48,864 | 39,636 | 36,811 | 30,406 |
| Total current liabilities | US$ in thousands | 56,226 | 58,693 | 53,591 | 56,517 | 49,040 | 41,494 | 42,350 | 42,803 |
| Quick ratio | 5.66 | 5.85 | 6.50 | 6.05 | 7.95 | 9.19 | 9.13 | 9.18 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($167,299K
+ $95,111K
+ $55,928K)
÷ $56,226K
= 5.66
The quick ratio of Cytek Biosciences Inc has been consistently strong over the past several quarters, indicating a robust ability to meet its short-term obligations using its most liquid assets. The ratio has ranged from 5.66 to 13.54, with the highest being in the latest quarter. This suggests that the company has a significant amount of highly liquid assets relative to its current liabilities, providing a strong cushion for any short-term financial challenges. The increasing trend in the quick ratio over the quarters reflects a positive liquidity position for Cytek Biosciences Inc, which may enhance its financial stability and ability to weather uncertainties in the business environment.
Peer comparison
Dec 31, 2023